Candel Therapeutics annual current ratio
2020
2021
2022
2023
2024
2025
Candel Therapeutics Current Ratio Growth & History (CADL)
Candel Therapeutics's current ratio was 13.49 for fiscal 2025.
View full Candel Therapeutics company overviewCandel Therapeutics annual current ratio history
| Fiscal year | Period ended | Current ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 13.49 | 10.73 | +387.79% |
| 2024 | 2024-12-31 | 2.77 | 0.17 | +6.62% |
| 2023 | 2023-12-31 | 2.59 | −10.22 | −79.75% |
| 2022 | 2022-12-31 | 12.81 | −3.03 | −19.12% |
| 2021 | 2021-12-31 | 15.84 | 8.38 | +112.44% |
| 2020 | 2020-12-31 | 7.46 | — | — |
Candel Therapeutics quarterly current ratio
Q4.20
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Current ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 16.09 | 9.05 | +128.58% |
| Q1 2026 | 2026-03-31 | 28.05 | 23.40 | +504.26% |
| Q4 2025 | 2025-12-31 | 13.49 | 10.73 | +387.79% |
| Q3 2025 | 2025-09-30 | 8.25 | 7.06 | +596.26% |
| Q2 2025 | 2025-06-30 | 7.04 | 5.42 | +333.45% |
| Q1 2025 | 2025-03-31 | 4.64 | 2.64 | +131.54% |
| Q4 2024 | 2024-12-31 | 2.77 | 0.17 | +6.62% |
| Q3 2024 | 2024-09-30 | 1.18 | −3.18 | −72.88% |
| Q2 2024 | 2024-06-30 | 1.62 | −4.91 | −75.15% |
| Q1 2024 | 2024-03-31 | 2.00 | −9.81 | −83.04% |
| Q4 2023 | 2023-12-31 | 2.59 | −10.22 | −79.75% |
| Q3 2023 | 2023-09-30 | 4.37 | −9.04 | −67.42% |
| Q2 2023 | 2023-06-30 | 6.54 | −8.32 | −56.00% |
| Q1 2023 | 2023-03-31 | 11.82 | −5.66 | −32.39% |
| Q4 2022 | 2022-12-31 | 12.81 | −3.03 | −19.12% |
| Q3 2022 | 2022-09-30 | 13.41 | −7.28 | −35.19% |
| Q2 2022 | 2022-06-30 | 14.86 | 9.42 | +173.33% |
| Q1 2022 | 2022-03-31 | 17.48 | — | — |
| Q4 2021 | 2021-12-31 | 15.84 | 8.38 | +112.44% |
| Q3 2021 | 2021-09-30 | 20.68 | — | — |
| Q2 2021 | 2021-06-30 | 5.44 | — | — |
| Q4 2020 | 2020-12-31 | 7.46 | — | — |
Candel Therapeutics current ratio trends
Over the last five fiscal years, Candel Therapeutics's current ratio increased from 7.46 to 13.49, a change of 6.03. The latest reported quarter, Q2 2026, shows 16.09.
About the metric
What the current ratio means
The current ratio compares short-term assets with obligations due within roughly one year. A higher ratio generally indicates more short-term balance-sheet coverage, but normal levels vary by industry and business model.
Calculation and source
How the current ratio is calculated
TickerStat calculates the current ratio as SEC-reported current assets divided by SEC-reported current liabilities for the same balance-sheet date. Periods without a positive current-liability value are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Candel Therapeutics source filings ↗